Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy - PubMed (original) (raw)

Case Reports

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy

Stephan Stilgenbauer et al. N Engl J Med. 2002.

No abstract available

PubMed Disclaimer

Similar articles

• The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53.
  Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D. Osuji NC, et al. Haematologica. 2005 Oct;90(10):1435-6. Haematologica. 2005. PMID: 16219582 Review.
• CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
  Dumont FJ. Dumont FJ. Expert Rev Anticancer Ther. 2002 Feb;2(1):23-35. doi: 10.1586/14737140.2.1.23. Expert Rev Anticancer Ther. 2002. PMID: 12113063 Review.
• Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.
  Wolff D, Steiner B, Stilgenbauer S, Kahl C, Leithäuser M, Junghanss C, Wilhelm S, Kleine HD, Zimmermann R, Hartung G, Casper J, Freund M. Wolff D, et al. Eur J Haematol. 2004 Feb;72(2):145-8. doi: 10.1046/j.0902-4441.2003.00181.x. Eur J Haematol. 2004. PMID: 14962253
• Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
  Thachil J, Salim R. Thachil J, et al. Leuk Res. 2007 Jul;31(7):1025-6. doi: 10.1016/j.leukres.2006.08.012. Epub 2006 Sep 26. Leuk Res. 2007. PMID: 17005249 No abstract available.
• Advances in the use of alemtuzumab in CLL.
  Stilgenbauer S. Stilgenbauer S. Clin Adv Hematol Oncol. 2008 Jan;6(1):23-4. Clin Adv Hematol Oncol. 2008. PMID: 18322437 Review. No abstract available.

Cited by

• Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL.
  Cuesta-Mateos C, Juárez-Sánchez R, Mateu-Albero T, Loscertales J, Mol W, Terrón F, Muñoz-Calleja C. Cuesta-Mateos C, et al. MAbs. 2021 Jan-Dec;13(1):1917484. doi: 10.1080/19420862.2021.1917484. MAbs. 2021. PMID: 33944659 Free PMC article.
• Prognosis Factors in Chronic Lymphocytic Leukemia.
  Ivanescu AM, Oprea M, Momanu R, Coles E, Colita A, Lupu AR. Ivanescu AM, et al. J Med Life. 2012 Oct-Dec;5(Spec Issue):48-53. J Med Life. 2012. PMID: 31803286 Free PMC article.
• Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.
  García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. García-Martínez E, et al. Oncoimmunology. 2018 Feb 15;7(6):e1433982. doi: 10.1080/2162402X.2018.1433982. eCollection 2018. Oncoimmunology. 2018. PMID: 29872569 Free PMC article. Review.
• Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.
  Cuesta-Mateos C, Alcaraz-Serna A, Somovilla-Crespo B, Muñoz-Calleja C. Cuesta-Mateos C, et al. Front Immunol. 2018 Jan 17;8:1936. doi: 10.3389/fimmu.2017.01936. eCollection 2017. Front Immunol. 2018. PMID: 29387053 Free PMC article. Review.
• Management of Chronic Lymphocytic Leukemia in the Elderly.
  Barrientos JC. Barrientos JC. Cancer Control. 2015 Oct;22(4 Suppl):17-23. doi: 10.1177/107327481502204s04. Cancer Control. 2015. PMID: 26618342 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal